PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth 0-5% – Limited. Howard Marks would question whether cost pressures or competition are capping margin gains.
8.25%
EBIT growth 5-10% – Moderate. Peter Lynch might look for ways the firm could optimize costs to boost EBIT further.
8.25%
Operating income growth 5-10% – Moderate. Peter Lynch would evaluate product-level profitability to see if certain segments could accelerate growth.
12.55%
Net income growth 10-15% – Solid. Seth Klarman would verify if cost control or pricing is driving consistent profit expansions.
15.52%
EPS growth 15-25% – Very strong. Benjamin Graham might verify if any one-time gains or tax benefits artificially inflate EPS.
15.52%
Diluted EPS growth 15-25% – Very strong. Benjamin Graham would verify that no large one-time items are skewing the diluted figure.
3.21%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
3.21%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth 15-20% – Very strong. Benjamin Graham would ensure that working capital changes aren’t inflating short-term cash flow artificially.
18.52%
FCF growth 15-20% – Strong. Benjamin Graham might verify whether large asset sales or one-time items artificially boosted free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
77.11%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
-27.06%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
72.83%
10Y net income/share CAGR above 15% – Exceptional long-term profit growth. Benjamin Graham would confirm if these gains hold through economic cycles.
70.62%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
-36.68%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
109.68%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-48.78%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-45.28%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
A negative 3Y dividend/share CAGR suggests recent cuts. Benjamin Graham confirms if a short-term profit dip or strategic pivot caused them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-20.44%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
-5.39%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
4.88%
R&D growth 0-10% – Balanced approach. Seth Klarman sees manageable cost if new products are still in development.
-40.17%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.